Unlock stock picks and a broker-level newsfeed that powers Wall Street.

Taipei Exchange - Delayed Quote TWD

VBI (4170.TWO)

Compare
12.50
-0.30
(-2.34%)
At close: April 11 at 2:19:21 PM GMT+8
Loading Chart for 4170.TWO
  • Previous Close 12.80
  • Open 12.50
  • Bid 12.10 x --
  • Ask 12.40 x --
  • Day's Range 11.90 - 12.50
  • 52 Week Range 10.40 - 21.10
  • Volume 35,711
  • Avg. Volume 53,403
  • Market Cap (intraday) 547.143M
  • Beta (5Y Monthly) -0.02
  • PE Ratio (TTM) --
  • EPS (TTM) -0.46
  • Earnings Date --
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

Vectorite Biomedical Inc. engages in the research and development of biotechnology in Taiwan and internationally. It offers cell preparation product manufacturing; and collection, processing, and storage management of immune cells. The company's cell preparation products are used in the field of infectious diseases and inflammation, cancer, and tumor diseases. Vectorite Biomedical Inc. was founded in 1993 and is based in New Taipei City, Taiwan.

www.vectorite.com.tw

--

Full Time Employees

December 31

Fiscal Year Ends

Recent News: 4170.TWO

View More

Performance Overview: 4170.TWO

Trailing total returns as of 4/11/2025, which may include dividends or other distributions. Benchmark is TSEC CAPITALIZATION WEIGHTED ST (^TWII) .

YTD Return

4170.TWO
12.28%
TSEC CAPITALIZATION WEIGHTED ST (^TWII)
15.22%

1-Year Return

4170.TWO
20.38%
TSEC CAPITALIZATION WEIGHTED ST (^TWII)
5.90%

3-Year Return

4170.TWO
8.23%
TSEC CAPITALIZATION WEIGHTED ST (^TWII)
14.55%

5-Year Return

4170.TWO
2.72%
TSEC CAPITALIZATION WEIGHTED ST (^TWII)
92.26%

Compare To: 4170.TWO

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 4170.TWO

View More

Valuation Measures

Annual
As of 4/11/2025
  • Market Cap

    547.14M

  • Enterprise Value

    353.86M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    10.23

  • Price/Book (mrq)

    1.31

  • Enterprise Value/Revenue

    6.62

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -37.74%

  • Return on Assets (ttm)

    -3.47%

  • Return on Equity (ttm)

    -4.71%

  • Revenue (ttm)

    53.47M

  • Net Income Avi to Common (ttm)

    -20.18M

  • Diluted EPS (ttm)

    -0.46

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    193.28M

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    -10.63M

Research Analysis: 4170.TWO

View More

Company Insights: 4170.TWO

Research Reports: 4170.TWO

View More

People Also Watch